Publication List Japanese
2023/09/13
ゼブラフィッシュ発生毒性学とデジタルトランスフォーメーション
2023/02/21
患者がん移植モデル(PDX)とターゲットバリデーション
2021/06/29
ハイスループットゼブラフィッシュ発生毒性試験プロトコルの確立
2020/05/29
自動ゼブラフィッシュ創薬のインパクト
2019/11/02
患者がん移植ゼブラフィッシュモデルによるプレシジョンメディシン
》ミトコンドリア機能制御による有毛細胞保護薬のシステムズ薬理学
2015/03/18
ミトコンドリア機能制御による有毛細胞保護薬のシステムズ薬理学
笹川翔太1、西村有平1,2,3,4,5、村上宗一郎1、芦川芳史1、弓削瑞葵1、有吉美稚子1、川瀬玲子1、田中利男1,2,3,4,5
1三重大学大学院医学系研究科薬理ゲノミクス（三重大・院・医・薬理ゲノミクス）
2三重大・院・医・システムズ薬理学
3三重大・メディカルゼブラフィッシュ研究センター
4三重大・生命科学研セ・バイオインフォ
5三重大・新産業創成研究拠点
Dysfunction of mitochondria contributes to the pathogenesis of many diseases, including neurodegenerative diseases such as Alzheimer’s disease, metabolic disorders such as Diabetes mellitus, and hearing loss caused by aging, noise or clinical drugs. Pharmacological approaches targeting mitochondria may be beneficial for patients with these diseases. These include increasing mitochondrial biogenesis, reactive oxygen species scavenging, targeting mitochondrial dynamics, the membrane fluidity and plasticity. However, the pattern of mitochondrial dysfunction can be complicated. Drug screening using in vivo models for these diseases is indispensable to discover drugs that can ameliorate diseases without detectable toxicity. In this study, we used zebrafish as an in vivo model of drug-induced hearing loss and performed screening of mitochondria-targeted drugs. We were able to identify compounds that protected auditory hair cells against drug-induced damage by modulating mitochondrial functions. These results support zebrafish’s potential for in vivo efficacy and toxicity screening of mitochondria-targeted drugs.